ELI LILLY AND COMPANY Operating Leases, Rent Expense
ELI LILLY AND COMPANY (LLY) reported Operating Leases, Rent Expense of $175.70 million for the 12-month period ending 2018-12-31, per its 8-K filed 2019-10-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2019-10-24
- ELI LILLY AND COMPANY operating leases, rent expense for fiscal 2015 was $225.70M, a 0.70% decline from fiscal 2014.
- ELI LILLY AND COMPANY operating leases, rent expense for fiscal 2014 was $227.30M, a 0.04% increase from fiscal 2013.
- ELI LILLY AND COMPANY operating leases, rent expense for fiscal 2013 was $227.20M, a 13.35% decline from fiscal 2012.
- ELI LILLY AND COMPANY operating leases, rent expense for fiscal 2012 was $262.20M, a 1.94% decline from fiscal 2011.
| Period end | Operating Leases, Rent Expense 12 month | Operating Leases, Rent Expense 12 month as first filed |
|---|---|---|
| 2018-12-31 | $175.70M 8-K · filed 2019-10-24 | $223.20M 10-K · filed 2019-02-19 |
| 2017-12-31 | $177.40M 8-K · filed 2019-10-24 | $224.50M 10-K · filed 2018-02-20 |
| 2016-12-31 | $179.20M 8-K · filed 2019-10-24 | $221.00M 10-K · filed 2017-02-21 |
| 2015-12-31 | $225.70M 10-K · filed 2018-02-20 | |
| 2014-12-31 | $227.30M 10-K · filed 2017-02-21 | |
| 2013-12-31 | $227.20M 10-K · filed 2016-02-19 | |
| 2012-12-31 | $262.20M 10-K · filed 2015-02-19 | $285.80M 10-K · filed 2013-02-21 |
| 2011-12-31 | $267.40M 10-K · filed 2014-02-19 | $353.40M 10-K · filed 2012-02-24 |
| 2010-12-31 | $255.70M 10-K · filed 2013-02-21 | $339.30M 10-K · filed 2011-02-22 |
| 2009-12-31 | $337.80M 10-K · filed 2012-02-24 | |
| 2008-12-31 | $327.40M 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |